<DOC>
	<DOCNO>NCT00278902</DOCNO>
	<brief_summary>This Phase 1 study patient advance solid tumor receive investigational study drug ARRY-334543 . This study 2 part . In first part , patient receive increase dos study drug ( 2 dose schedule evaluate ) order achieve high dose possible cause unacceptable side effect . Approximately 70 patient US Canada enrol Part 1 ( Completed ) . In second part study , patient receive best dose ( ) schedule ( ) study drug determine first part study follow see side effect study drug cause effectiveness , , treat cancer . Approximately 40 patient US Canada enrol Part 2 ( Completed ) .</brief_summary>
	<brief_title>A Study ARRY-334543 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Key Inclusion Criteria ( Part 2 ) : Histologically cytologically confirm diagnosis ErbB2+ breast cancer , pancreatic , squamous cell head neck , hepatocellular , hepatobiliary , glioblastoma , ovarian , prostate , upper GI , colorectal , non small cell lung , bladder cancer relevant cancer approve advance Sponsor . Measurable disease ( least 1 target lesion ) accord modify RECIST . Failed least one previous therapeutic regimen either longer candidate standard therapy , standard therapy available , choose pursue standard therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . Must consent allow Sponsor access archival histological specimen predose tumor biopsy . Additional criterion exist . Key Exclusion Criteria ( Part 2 ) : Uncontrolled symptomatic brain metastasis ( patient brain metastasis steroid , steroid dose must stable least 30 day ) . Use investigational medication device within 30 day prior first dose study drug . Major surgery within 30 day prior first dose study drug . Radiotherapy chemotherapy within 28 day prior first dose study drug ( include palliative radiotherapy focal site ) . Pregnancy lactation . Known positive serology human immunodeficiency virus ( HIV ) , hepatitis B and/or hepatitis C. Of note , patient hepatocellular carcinoma , may enrol even positive hepatitis B and/or hepatitis C. Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>ErbB2+ Breast Cancer</keyword>
	<keyword>HER2+ Breast Cancer</keyword>
</DOC>